Investing
Novartis’ Sandoz to generate additional $3 billion in net sales over next five years
© Reuters. FILE PHOTO: The company’s logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann
LONDON (Reuters) – Novartis’ soon to be spun off generics division Sandoz is expected to expand its pipeline and generate an additional $3 billion in net sales over the next five years, the Swiss group said on Thursday.
The company intends to carve out Sandoz, which sells generics and biosimilars – cheap versions of biologic drugs made from living organisms – and generated about $9 billion in sales last year, to sharpen its focus on its patented prescription medicines in the second half of this year.
Read the full article here
-
Side Hustles6 days ago
Expand Your Global Reach with Access to More Than 150 Languages for Life
-
Side Hustles7 days ago
Kickstart Your Year With These Entrepreneurial Health Checkups
-
Side Hustles5 days ago
KFC Announces Saucy, a Chicken Tenders-Focused Spinoff
-
Side Hustles6 days ago
This AI is the Key to Unlocking Explosive Sales Growth in 2025
-
Investing5 days ago
Palantir, Anduril join forces with tech groups to bid for Pentagon contracts, FT reports By Reuters
-
Side Hustles4 days ago
4 Ways Content Can Make or Break the Customer Experience
-
Make Money7 days ago
Brace for Impact: 5 Potential Stock Market Crash Triggers in 2025
-
Passive Income7 days ago
How to Motivate, Inspire and Energize Your Employees